RAC1, which has been demonstrated to be upregulated in enzalutamide-resistant prostate cancer cells, plays a crucial role in enzalutamide resistance and could be a potential target for the treatment of castration-resistant prostate cancer (Chen et al., 2020). The gene discussed is RAC1; the disease is prostate carcinoma.